Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:IVA NASDAQ:MNPR NASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.55-0.8%$4.95$2.25▼$6.75$628.02M2.211.80 million shs585,736 shsIVAInventiva$5.18-3.4%$5.05$1.60▼$6.55$495.14M0.6629,330 shs153,490 shsMNPRMonopar Therapeutics$99.64+1.1%$51.98$4.50▼$105.00$614.78M1.4243,955 shs46,165 shsTHTXTheratechnologies$3.42+0.9%$3.28$1.12▼$3.40$157.21M0.51735,945 shs3.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways+5.77%+14.38%+32.53%+77.42%+9.45%IVAInventiva-2.90%-9.31%-0.19%+62.18%+224.85%MNPRMonopar Therapeutics+0.05%+16.33%+137.63%+157.63%+1,745.88%THTXTheratechnologies0.00%0.00%+4.56%+8.54%+182.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.55-0.8%$4.95$2.25▼$6.75$628.02M2.211.80 million shs585,736 shsIVAInventiva$5.18-3.4%$5.05$1.60▼$6.55$495.14M0.6629,330 shs153,490 shsMNPRMonopar Therapeutics$99.64+1.1%$51.98$4.50▼$105.00$614.78M1.4243,955 shs46,165 shsTHTXTheratechnologies$3.42+0.9%$3.28$1.12▼$3.40$157.21M0.51735,945 shs3.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways+5.77%+14.38%+32.53%+77.42%+9.45%IVAInventiva-2.90%-9.31%-0.19%+62.18%+224.85%MNPRMonopar Therapeutics+0.05%+16.33%+137.63%+157.63%+1,745.88%THTXTheratechnologies0.00%0.00%+4.56%+8.54%+182.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 2.63Moderate Buy$16.29148.64% UpsideIVAInventiva 2.63Moderate Buy$16.14211.88% UpsideMNPRMonopar Therapeutics 2.82Moderate Buy$97.33-2.32% DownsideTHTXTheratechnologies 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest THTX, IVA, CMPS, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.0010/8/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IVAInventivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$80.00 ➝ $142.0010/2/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$77.00 ➝ $115.009/30/2025IVAInventivaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/29/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$70.00 ➝ $105.009/27/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IVAInventivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AIVAInventiva$9.95M49.76N/AN/A($1.21) per share-4.28MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ATHTXTheratechnologies$84.38M1.86N/AN/A($0.55) per share-6.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)THTXTheratechnologies-$8.31M-$0.19N/A48.84N/A-10.85%N/A-9.83%10/9/2025 (Estimated)Latest THTX, IVA, CMPS, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/A7/9/2025Q2 2025THTXTheratechnologies-$0.01-$0.09-$0.08-$0.09$24.30 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.168.828.82IVAInventivaN/A2.96N/AMNPRMonopar TherapeuticsN/A33.9333.93THTXTheratechnologiesN/A0.840.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%IVAInventiva19.06%MNPRMonopar Therapeutics1.83%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%IVAInventiva32.00%MNPRMonopar Therapeutics20.50%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableTHTX, IVA, CMPS, and MNPR HeadlinesRecent News About These CompaniesTheratechnologies (NASDAQ:THTX) Trading 0.9% Higher - Still a Buy?October 8 at 2:43 AM | americanbankingnews.comTheratechnologies Announces Completion of Acquisition by Future PakSeptember 25, 2025 | globenewswire.comTheratechnologies Inc. (NASDAQ:THTX) Short Interest UpdateSeptember 17, 2025 | marketbeat.comTheratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 16, 2025 | financialpost.comFTheratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 16, 2025 | globenewswire.comTheratechnologies shareholders approve proposed acquisition by Future PakSeptember 12, 2025 | msn.comTheratechnologies Shareholders Approve Acquisition by Future Pak AffiliateSeptember 12, 2025 | tipranks.comTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12, 2025 | financialpost.comFTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12, 2025 | globenewswire.comShort Interest in Theratechnologies Inc. (NASDAQ:THTX) Expands By 31.4%September 10, 2025 | marketbeat.comTheratechnologies announces availability of EGRIFTA WRSeptember 6, 2025 | msn.comTheratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and LipodystrophySeptember 5, 2025 | globenewswire.comTheratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future PakSeptember 2, 2025 | globenewswire.comTheratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future PakAugust 18, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the Second Quarter 2025July 9, 2025 | globenewswire.comTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7, 2025 | seekingalpha.comFuture Pak to buy Theratechnologies for $254 millionJuly 4, 2025 | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3, 2025 | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3, 2025 | cantechletter.comCNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming SectorBy Nathan Reiff | October 7, 2025Broadcom’s VMware Push Takes Aim at Microsoft, Google, & AmazonBy Leo Miller | October 6, 2025Behind D-Wave's Massive Week (And Why Rivals Also Popped)By Nathan Reiff | October 6, 2025THTX, IVA, CMPS, and MNPR Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$6.55 -0.05 (-0.76%) As of 12:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Inventiva NASDAQ:IVA$5.18 -0.18 (-3.43%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Monopar Therapeutics NASDAQ:MNPR$99.64 +1.07 (+1.09%) As of 12:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Theratechnologies NASDAQ:THTX$3.42 +0.03 (+0.86%) Closing price 09/25/2025Extended Trading$3.42 0.00 (0.00%) As of 09/25/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
